Impact of climate change on pediatric health outcomes.

Glob Health ActionApr 15, 2026 (epub)
Clinical ResearchPediatricsOpen access

Mohammed Abbas, Dhafer Obead Alqahtani

✦ AI-curated · Sources linked

In 30 seconds

This systematic review assessed evidence linking climate exposures with health outcomes in children. It included 23 peer-reviewed studies published in 2000–2025, spanning different regions and study designs, and evaluated acute and chronic outcomes. The narrative synthesis found consistent associations between air pollutants—particularly PM2.5, NO2 and O3—and respiratory morbidity, asthma prevalence and hospitalization. Higher temperatures and heat waves were associated with heat illness, dehydration and febrile states, while extreme weather, especially floods, was linked to diarrheal and vector-related infections. Most studies had low to moderate risk of bias.

Key findings

  • PM2.5, NO2 and O3 were consistently linked with pediatric respiratory morbidity, asthma prevalence and hospitalization.
  • Higher temperatures and heat waves were associated with heat illness, dehydration and febrile states in infants and young children.
  • Extreme weather events, particularly floods, were linked with diarrheal and vector-related infections, especially in low-resource settings.
  • The review included 23 studies; evidence from low-income countries was limited.

Why it matters

The synthesis indicates that several climate-related exposures are associated with important pediatric health outcomes across varied settings. Recognising these patterns can inform assessment of environmental risks to children and support consideration of climate-related threats in child health planning. The limited evidence from low-income countries and the frequent study of exposures in isolation also identify gaps in the evidence base.

What to keep in mind

The review found substantial regional and methodological differences, limited evidence from low-income countries, and that most studies assessed exposures individually, potentially underestimating cumulative or compound risks.

Source

Published in Glob Health Action. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.